{"id":"W2245359169","doi":"10.1200/jco.2013.31.4_suppl.337","title":"Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Capecitabine; Hazard ratio; Bevacizumab; Clinical endpoint; Internal medicine; Colorectal cancer; Confidence interval; Randomized controlled trial; Cancer; Cape; Surgery; Oncology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001929073,0.0007329586,0.00111789,0.000265899,0.0001920502,0.0006055699,0.0004232976,0.0007460525,0.001775822],"category_scores_gemma":[0.001170722,0.0003082378,0.0009254038,0.0003222466,0.0004751912,0.0004613158,0.0002576777,0.001538636,0.0002517632],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005392046,"about_ca_system_score_gemma":0.000854554,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000939183,"about_ca_topic_score_gemma":0.002880085,"domain_scores_codex":[0.9997035,0.0001913781,0.00001789768,0.00002912231,0.00002344204,0.00003468139],"domain_scores_gemma":[0.9993807,0.0001463733,0.0001548326,0.00002551729,0.00003029744,0.0002622962],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.887767,0.01450371,0.005685646,0.000956963,0.001554637,0.0001049397,0.0001068509,0.001183863,0.01025031,0.0001545405,0.003049566,0.07468197],"study_design_scores_gemma":[0.8245321,0.1586767,0.01129466,0.00008465875,0.0009079389,0.0001402078,0.0000304033,0.000897685,0.00113283,0.0001065278,0.00218155,0.0000148048],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880779,0.007659307,0.0004101421,0.000605039,0.0001612424,0.001325419,0.0006457049,0.00004336724,0.001071743],"genre_scores_gemma":[0.9865687,0.006275273,0.001610238,0.000773524,0.0002213678,0.001441337,0.001885864,0.00001557311,0.001208239],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001929073,"threshold_uncertainty_score":0.01020205,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06477086103378332,"score_gpt":0.4269228190159641,"score_spread":0.3621519579821808,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}